Cantor Revised Target, Is this UBS all over again?
This exactly the same #$%$ that UBS pulled to drive stock down to 10.00. The whole Biotech sector has been down past couple of days and then add Cantor. This is not about 901 as almost no one has assigned any value to this compound. NSCLC is like Lupus, long list of failures before it so analysts give it a 10% chance of probability. This was merely an excuse to drive it down as it will be the last opportunity to do so since Sales will drive the news and value.